Predicting Biotech Breakouts Before They Happen
ScanScor was built from the ground up to explore a difficult question:
can AI help predict the future?
Created by a veteran web developer who fell head-over-heels in love with artificial intelligence,
ScanScor puts that curiosity to the test in one of the most demanding arenas imaginable — biotech investing.
See Catalysts Early
Biotech rewards those who recognize real-world catalysts before price action makes them obvious. ScanScor continuously analyzes hundreds of biotech companies to surface early signals tied to clinical trials, regulatory milestones, insider activity, conferences, and shifting sentiment.
Transparent AI Predictions
ScanScor is not a black box. Every prediction is grounded in observable data, documented signals, and a clear analytical trail. AI is used as an assistant — not an oracle — helping translate complex information into structured, testable forecasts.
News Alerts & NDAPR
ScanScor actively monitors biotech news in real time and delivers alerts via email and Telegram. At the core of the system is NDAPR (News-Driven AI Alert & Prediction Revision), which evaluates breaking news and determines whether existing predictions should stand, evolve, or be updated.
AI Alerts That Adapt
Predictions are not static. As new information arrives, ScanScor’s AI Alerts reassess the evolving story, helping users stay aligned with the thesis rather than reacting to noise. The goal is clarity — not constant interruption.
Verification & Accountability
ScanScor measures outcomes. Successes are documented. Misses are logged. A public test batch of 124 predictions from July 8, 2025 is preserved and independently verifiable via archive.org for anyone who wishes to audit the results.
This website performs a function that serves its designer.
He hopes you find it useful as well.
If you’d like to reach out, feel free to drop him a line:
[email protected]